Donald E. Born
YOU?
Author Swipe
View article: 2 ADHERENCE TO CLINICAL SURVEILLANCE GUIDELINES IN VON HIPPEL-LINDAU (VHL) DISEASE: EVALUATING THE IMPACT OF A COORDINATED CARE CENTRE IMPLEMENTATION IN BC
2 ADHERENCE TO CLINICAL SURVEILLANCE GUIDELINES IN VON HIPPEL-LINDAU (VHL) DISEASE: EVALUATING THE IMPACT OF A COORDINATED CARE CENTRE IMPLEMENTATION IN BC Open
VHL is a rare hereditary cancer syndrome, predisposing to the development of multiorgan tumour growth including CNS and retinal hemangioblastomas. While guidelines for screening and management of vHL exist, adherence is variable. The devel…
View article: Malignant transformation of cervical ganglioglioma to glioblastoma in a pediatric patient: illustrative case
Malignant transformation of cervical ganglioglioma to glioblastoma in a pediatric patient: illustrative case Open
BACKGROUND Gangliogliomas are low-grade gliomas typically found in the temporal lobes with a low rate of malignant transformation. In rare cases, they may be found in the spinal axis. OBSERVATIONS An 8-year-old boy presented with 2 months …
View article: Reduced Fascicle Area Demonstrated in Ilioinguinal Nerves Resected from Primary Inguinal Herniorrhaphy Patients as Evidence of Compression Neuropathy
Reduced Fascicle Area Demonstrated in Ilioinguinal Nerves Resected from Primary Inguinal Herniorrhaphy Patients as Evidence of Compression Neuropathy Open
Background and Aim . Previous studies have reported 63% of primary inguinal hernia patients present with apparent enlargement of the ilioinguinal nerve beyond the inguinal ring. This may be due to hernia-related pressure on the canal porti…
View article: Neuroinvasive <i>Francisella tularensis</i> Infection: Report of 2 Cases and Review of the Literature
Neuroinvasive <i>Francisella tularensis</i> Infection: Report of 2 Cases and Review of the Literature Open
Background Neuroinvasive infection with Francisella tularensis, the causative agent of tularemia, is rare. Establishing clinical suspicion is challenging if risk factors or clinical features classically associated with tularemia are absent…
View article: Vascular anomaly, lipoma, and polymicrogyria associated with schizencephaly: developmental and diagnostic insights. Illustrative case
Vascular anomaly, lipoma, and polymicrogyria associated with schizencephaly: developmental and diagnostic insights. Illustrative case Open
BACKGROUND Schizencephaly is an uncommon central nervous system malformation. Intracranial lipomas are also rare, accounting for approximately 0.1% of brain “tumors.” They are believed to be derived from a persistent meninx primitiva, a ne…
View article: Supplementary Data from Phosphoproteomic and Kinomic Signature of Clinically Aggressive Grade I (1.5) Meningiomas Reveals RB1 Signaling as a Novel Mediator and Biomarker
Supplementary Data from Phosphoproteomic and Kinomic Signature of Clinically Aggressive Grade I (1.5) Meningiomas Reveals RB1 Signaling as a Novel Mediator and Biomarker Open
Figure S5
View article: Data from Macrophage Exclusion after Radiation Therapy (MERT): A First in Human Phase I/II Trial using a CXCR4 Inhibitor in Glioblastoma
Data from Macrophage Exclusion after Radiation Therapy (MERT): A First in Human Phase I/II Trial using a CXCR4 Inhibitor in Glioblastoma Open
Purpose:Preclinical studies have demonstrated that postirradiation tumor revascularization is dependent on a stromal cell–derived factor-1 (SDF-1)/C-X-C chemokine receptor type 4 (CXCR4)-driven process in which myeloid cells are recruited …
View article: Supplementary Figure S3 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Supplementary Figure S3 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma Open
Evaluation of PKM2 expression in U87-GFP/luc orthotopic GBM
View article: Supplementary Data from Phosphoproteomic and Kinomic Signature of Clinically Aggressive Grade I (1.5) Meningiomas Reveals RB1 Signaling as a Novel Mediator and Biomarker
Supplementary Data from Phosphoproteomic and Kinomic Signature of Clinically Aggressive Grade I (1.5) Meningiomas Reveals RB1 Signaling as a Novel Mediator and Biomarker Open
Table S3
View article: Supplementary Data from Phosphoproteomic and Kinomic Signature of Clinically Aggressive Grade I (1.5) Meningiomas Reveals RB1 Signaling as a Novel Mediator and Biomarker
Supplementary Data from Phosphoproteomic and Kinomic Signature of Clinically Aggressive Grade I (1.5) Meningiomas Reveals RB1 Signaling as a Novel Mediator and Biomarker Open
Table S8
View article: Supplementary Figure S2 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Supplementary Figure S2 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma Open
Comparative metabolic PET/CT imaging in U87-GFP/luc GBM mice
View article: Supplementary Figure S2 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Supplementary Figure S2 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma Open
Comparative metabolic PET/CT imaging in U87-GFP/luc GBM mice
View article: Data from Macrophage Exclusion after Radiation Therapy (MERT): A First in Human Phase I/II Trial using a CXCR4 Inhibitor in Glioblastoma
Data from Macrophage Exclusion after Radiation Therapy (MERT): A First in Human Phase I/II Trial using a CXCR4 Inhibitor in Glioblastoma Open
Purpose:Preclinical studies have demonstrated that postirradiation tumor revascularization is dependent on a stromal cell–derived factor-1 (SDF-1)/C-X-C chemokine receptor type 4 (CXCR4)-driven process in which myeloid cells are recruited …
View article: Supplementary Table S1 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Supplementary Table S1 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma Open
[18F]DASA-23 administered activity in healthy volunteers
View article: Supplementary Figure S1 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Supplementary Figure S1 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma Open
[18F]DASA-23 Radiosynthesis
View article: Supplementary Figure S8 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Supplementary Figure S8 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma Open
Imaging of IC-2
View article: Supplementary Table S3 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Supplementary Table S3 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma Open
Clinical Characteristics of patients imaged with [18F]DASA-23
View article: Data from Phosphoproteomic and Kinomic Signature of Clinically Aggressive Grade I (1.5) Meningiomas Reveals RB1 Signaling as a Novel Mediator and Biomarker
Data from Phosphoproteomic and Kinomic Signature of Clinically Aggressive Grade I (1.5) Meningiomas Reveals RB1 Signaling as a Novel Mediator and Biomarker Open
Purpose:Most World Health Organization (WHO) grade I meningiomas carry a favorable prognosis. Some become clinically aggressive with recurrence, invasion, and resistance to conventional therapies (grade 1.5; recurrent/progressive WHO grade…
View article: Supplementary Figure S8 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Supplementary Figure S8 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma Open
Imaging of IC-2
View article: Supplementary Figure S3 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Supplementary Figure S3 from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma Open
Evaluation of PKM2 expression in U87-GFP/luc orthotopic GBM
View article: Supplementary Data from Phosphoproteomic and Kinomic Signature of Clinically Aggressive Grade I (1.5) Meningiomas Reveals RB1 Signaling as a Novel Mediator and Biomarker
Supplementary Data from Phosphoproteomic and Kinomic Signature of Clinically Aggressive Grade I (1.5) Meningiomas Reveals RB1 Signaling as a Novel Mediator and Biomarker Open
Figure S2, S3, S4, S6, S7, S8, S9 and tables
View article: Supplementary Data from Phosphoproteomic and Kinomic Signature of Clinically Aggressive Grade I (1.5) Meningiomas Reveals RB1 Signaling as a Novel Mediator and Biomarker
Supplementary Data from Phosphoproteomic and Kinomic Signature of Clinically Aggressive Grade I (1.5) Meningiomas Reveals RB1 Signaling as a Novel Mediator and Biomarker Open
Table S4
View article: Supplementary Data from Phosphoproteomic and Kinomic Signature of Clinically Aggressive Grade I (1.5) Meningiomas Reveals RB1 Signaling as a Novel Mediator and Biomarker
Supplementary Data from Phosphoproteomic and Kinomic Signature of Clinically Aggressive Grade I (1.5) Meningiomas Reveals RB1 Signaling as a Novel Mediator and Biomarker Open
Table S6
View article: Supplementary Data from Phosphoproteomic and Kinomic Signature of Clinically Aggressive Grade I (1.5) Meningiomas Reveals RB1 Signaling as a Novel Mediator and Biomarker
Supplementary Data from Phosphoproteomic and Kinomic Signature of Clinically Aggressive Grade I (1.5) Meningiomas Reveals RB1 Signaling as a Novel Mediator and Biomarker Open
Figure S2, S3, S4, S6, S7, S8, S9 and tables
View article: Data from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma
Data from A Clinical PET Imaging Tracer ([<sup>18</sup>F]DASA-23) to Monitor Pyruvate Kinase M2–Induced Glycolytic Reprogramming in Glioblastoma Open
Purpose:Pyruvate kinase M2 (PKM2) catalyzes the final step in glycolysis, a key process of cancer metabolism. PKM2 is preferentially expressed by glioblastoma (GBM) cells with minimal expression in healthy brain. We describe the developmen…
View article: Supplementary Data from Phosphoproteomic and Kinomic Signature of Clinically Aggressive Grade I (1.5) Meningiomas Reveals RB1 Signaling as a Novel Mediator and Biomarker
Supplementary Data from Phosphoproteomic and Kinomic Signature of Clinically Aggressive Grade I (1.5) Meningiomas Reveals RB1 Signaling as a Novel Mediator and Biomarker Open
Supplementary Figures and Tables
View article: Supplementary Data from Phosphoproteomic and Kinomic Signature of Clinically Aggressive Grade I (1.5) Meningiomas Reveals RB1 Signaling as a Novel Mediator and Biomarker
Supplementary Data from Phosphoproteomic and Kinomic Signature of Clinically Aggressive Grade I (1.5) Meningiomas Reveals RB1 Signaling as a Novel Mediator and Biomarker Open
Table S6
View article: Supplementary Data from Phosphoproteomic and Kinomic Signature of Clinically Aggressive Grade I (1.5) Meningiomas Reveals RB1 Signaling as a Novel Mediator and Biomarker
Supplementary Data from Phosphoproteomic and Kinomic Signature of Clinically Aggressive Grade I (1.5) Meningiomas Reveals RB1 Signaling as a Novel Mediator and Biomarker Open
Table S7
View article: Supplementary Data from Phosphoproteomic and Kinomic Signature of Clinically Aggressive Grade I (1.5) Meningiomas Reveals RB1 Signaling as a Novel Mediator and Biomarker
Supplementary Data from Phosphoproteomic and Kinomic Signature of Clinically Aggressive Grade I (1.5) Meningiomas Reveals RB1 Signaling as a Novel Mediator and Biomarker Open
Table S3